在神经退行中准非编码RNA:治疗RNA模式和下一代传递技术的进步
Akshay Thakur1, Kaunava Roy Chowdhury1, Ankush Kumar2
1School of Pharmaceutical Sciences, CT University, Ludhiana, 142024, Punjab, India.
Current Alzheimer research
|January 27, 2026
概括
非编码RNA (ncRNA) 疗法在阿尔茨海默氏症和帕金森氏症等神经退行性疾病 (ND) 中表现有前途. 在RNA编辑和纳米技术的进步提高治疗效率和交付,为患者提供新的希望.
科学领域:
- 生物医学科学 生物医学科学
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
背景情况:
- 神经退行性疾病 (NDs) 是一个重大的全球健康挑战.
- 目前对ND的治疗方法往往控制症状,而不是解决根本原因.
- 非编码RNAs (ncRNAs) 已经成为与NDs相关的细胞过程中的关键调节者.
研究的目的:
- 审查针对神经退行性疾病的ncRNAs (miRNAs, lncRNAs, exosomal RNAs) 的治疗潜力.
- 探索计算和化学方法的进步,以提高ncRNA疗法的疗效.
- 讨论RNA编辑技术和纳米技术在克服交付和特异性挑战中的作用.
主要方法:
- 对基于ncRNA的ND治疗方法的文献综述.
- 对RNA结构和基因网络的计算工具的分析.
- 检查化学修饰和纳米技术用于RNA输送.
- 审查像CRISPR/Cas13这样的RNA编辑技术.
主要成果:
- 基于ncRNA的疗法,包括miRNAs和lncRNAs,在NDS中显示出调节疾病途径的潜力.
- 计算和化学策略已经提高了ncRNA疗法的稳定性,准确性和传递性.
- RNA编辑技术为治疗神经退行症提供了ncRNA表达的精确操纵.
- 纳米技术提供了解决方案,以高效和有针对性地将ncRNA传递给神经组织.
结论:
- 基于ncRNA的疗法代表了治疗神经退行性疾病的前沿.
- 持续的研究和技术创新对于实现ncRNAs的全部治疗潜力至关重要.
- 这些先进的疗法可以重新定义神经退行性疾病治疗和患者护理的未来.
相关概念视频
lncRNA - Long Non-coding RNAs
9.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.9K
lncRNA - Long Non-coding RNAs
3.6K
3.6K
siRNA - Small Interfering RNAs
18.6K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.6K
piRNA - Piwi-interacting RNAs
7.6K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
7.6K
Ribosomal RNA Synthesis
14.8K
Ribosome synthesis is a highly complex and coordinated process involving more than 200 assembly factors. The synthesis and processing of ribosomal components occurs not only in the nucleolus but also in the nucleoplasm and the cytoplasm of eukaryotic cells.
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
14.8K
RNA Interference
28.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.0K


